Relapsed Adult AML: Clinical Trials

12 trials for Relapsed Adult AML, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 3 unknown, 2 withdrawn, 1 active not recruiting. 12 Phase 2, 7 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 212Recruiting 4, Unknown 3, Withdrawn 2, Active not recruiting 1, Completed 1, Not yet recruiting 1
Phase 17Recruiting 2, Unknown 2, Withdrawn 2, Completed 1

Follow Relapsed Adult AML: new trials by email Literature Review of Relapsed Adult AML trials Research Report on Relapsed Adult AML

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Menin-Inhibitor Targeted Maintenance in AML
Revumenib, Placebo - Relapsed Adult AML, Stem Cell Transplant Complications
Phase 2Not yet recruitingCenter for International Blood and Marrow Transplant Research1462026-12-012026-06-22
Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
AdaptNK, Fludarabine, Cyclophosphamide - Relapsed Adult AML, Refractory AML
Phase 1 / Phase 2RecruitingMasonic Cancer Center, University of Minnesota182026-05-082026-05-19
Tislelizumab with Azacitidine in the Treatment of R/R AML
Aza, tislelizumab - Refractory AML, Relapsed Adult AML
Phase 1 / Phase 2WithdrawnInstitute of Hematology & Blood Diseases Hospital, China2024-10-052024-09-19
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
AzaCITIDine Oral Tablet, Xospata - AML, Adult, Refractory AML
Phase 2RecruitingFrench Innovative Leukemia Organisation332024-01-132025-03-24
Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT
Plerixafor - Relapsed Adult ALL, Relapsed Adult AML
Phase 2UnknownThe First Hospital of Jilin University282023-09-012023-11-21
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
Lintuzumab-Ac225, Venetoclax, Azacitidine - Acute Myeloid Leukemia, Relapsed Adult AML
Phase 1 / Phase 2WithdrawnActinium Pharmaceuticals2023-03-012023-07-20
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
venetoclax combining chidamide and azacitidine (VCA) - Leukemia, Myeloid, Acute, Relapsed Adult AML
Phase 2RecruitingThe First Affiliated Hospital of Xiamen University302022-01-122025-09-11
New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
CAHAG regimen, Placebo regimen - Acute Myeloid Leukemia, Refractory Acute Leukemia
Phase 2Active not recruitingThe First Affiliated Hospital of Soochow University212021-09-012026-03-19
Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)
Venetoclax Oral Tablet - Relapsed Adult AML, Refractory AML
Phase 1 / Phase 2CompletedTechnische Universität Dresden552020-04-062026-09-02
Venetoclax and Lintuzumab-Ac225 in AML Patients
Lintuzumab-Ac225, Venetoclax, Spironolactone - Acute Myeloid Leukemia, Relapsed Adult AML
Phase 1 / Phase 2UnknownActinium Pharmaceuticals382020-01-152023-08-04
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion - Leukemia, Myeloid, Acute, Refractory AML
Phase 1 / Phase 2RecruitingAptose Biosciences Inc.2402019-03-112025-08-26
Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)
GLIDE - Hematologic Cancer, Relapse Leukemia
Phase 1 / Phase 2UnknownCiusss de L'Est de l'Île de Montréal202017-02-062017-12-06

Narrower conditions

Leukemia, Myeloid, Acute (12)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Hematologic Neoplasms (1)  ·  Hodgkin Disease (1)  ·  Leukemia (1)  ·  Leukemia, Myelomonocytic, Chronic (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Multiple Myeloma (1)  ·  Myelodysplastic Syndromes (1)  ·  Recurrence (1)

Broader conditions

Hematologic Diseases (12)  ·  Hemic and Lymphatic Diseases (12)  ·  Leukemia, Myeloid (12)  ·  Neoplasms (12)  ·  Neoplasms by Histologic Type (12)  ·  Leukemia (11)  ·  Bone Marrow Diseases (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Leukemia, Lymphoid (2)  ·  Lymphatic Diseases (2)  ·  Lymphoproliferative Disorders (2)  ·  Blood Protein Disorders (1)  ·  Cardiovascular Diseases (1)  ·  Chronic Disease (1)

Interventions

Azacitidine (4)  ·  venetoclax (4)  ·  Cyclophosphamide (1)  ·  Infusions, Intravenous (1)  ·  Interleukin-2 (1)  ·  Spironolactone (1)  ·  cc-486 (1)  ·  fludarabine (1)  ·  gilteritinib (1)  ·  plerixafor (1)  ·  revumenib (1)  ·  tislelizumab (1)

Sponsors

Actinium Pharmaceuticals (2)  ·  Aptose Biosciences Inc. (1)  ·  Center for International Blood and Marrow Transplant Research (1)  ·  Ciusss de L'Est de l'Île de Montréal (1)  ·  French Innovative Leukemia Organisation (1)  ·  Institute of Hematology & Blood Diseases Hospital, China (1)  ·  Masonic Cancer Center, University of Minnesota (1)  ·  Technische Universität Dresden (1)  ·  The First Affiliated Hospital of Soochow University (1)  ·  The First Affiliated Hospital of Xiamen University (1)  ·  The First Hospital of Jilin University (1)

Countries

China (4)  ·  United States (3)  ·  Germany (2)  ·  Australia (1)  ·  Canada (1)  ·  France (1)  ·  New Zealand (1)  ·  South Korea (1)  ·  Spain (1)

Top investigators

Avinash Desai, MD (2)  ·  Bing Xu (1)  ·  Denis-Claude Roy, MD PhD (1)  ·  Long Su, PhD (1)  ·  Naval Daver, MD (1)  ·  Silvy Lachance, MD (1)  ·  Steven Devine, M.D (1)

Results publications

PMID 33347715, PMID 39665627, PMID 41791831

NIH funding

2023 (1)